6 Aleatorización y cegamiento

Introducción al Ensayo Clínico

Conceptos Básicos del Ensayo Clínico

• El Dr. Óscar Frenza Sueta introduce el tema de diseño de estudios epidemiológicos, enfocándose en ensayos clínicos.

• Se mencionan dos aspectos metodológicos importantes: aleatorización y cegamiento.

Aleatorización

• La aleatorización es la asignación aleatoria de tratamientos, donde cada individuo tiene un 50% de probabilidad de ser asignado a tratamiento A o B.

• El objetivo principal es eliminar sesgos del investigador en la selección del tratamiento y asegurar grupos comparables entre sí.

Importancia de la Comparabilidad

• Los grupos deben ser intercambiables en variables como edad, género y morbilidades para minimizar factores confusores.

• La aleatorización busca balancear tanto factores conocidos como desconocidos que podrían influir en los resultados.

Validación Estadística

Pruebas Estadísticas Válidas

• Garantiza que las pruebas estadísticas sean válidas, especialmente las bivariadas como chi cuadrada o T-student.

• En estudios observacionales sin aleatorización, se requieren ajustes por factores confusores mediante modelos multivariados.

Tipos de Aleatorización

Aleatorización Simple

• En la aleatorización simple, cada tratamiento se asigna independientemente a cada paciente con un 50% de probabilidad.

Problemas Potenciales

• Con muestras pequeñas pueden surgir desbalances debido a series largas con la misma asignación (ejemplo: varios pacientes consecutivos recibiendo el mismo tratamiento).

Aleatorización en Bloques

Estrategia para Evitar Desbalances

• La aleatorización en bloques ayuda a evitar desbalances al crear bloques con un número fijo de tratamientos (ejemplo: bloques de cuatro).

Ejemplo Práctico

• Un bloque puede contener una secuencia equilibrada (2 A y 2 B), asegurando que no haya series largas del mismo tratamiento.

Cegamiento en Ensayos Clínicos

Definición y Propósito

• El cegamiento implica que ni los investigadores ni los participantes sepan qué tratamiento recibe cada persona para evitar sesgos.

Riesgos Sin Cegamiento

• Si el investigador conoce la asignación, puede influir inconscientemente en el reclutamiento o evaluación según sus creencias sobre los tratamientos.

Asignación Adaptativa

Concepto General

• En la asignación adaptativa, el siguiente paciente se asigna basado en cómo le fue al anterior; si tuvo éxito, se repite el tratamiento exitoso.

Limitaciones Logísticas

• Esta estrategia requiere conocer resultados rápidamente; desenlaces lentos como mortalidad hacen esta técnica impráctica.

Administración de Asignaciones

Métodos Comunes

• Las empresas pueden centralizar la administración; métodos simples incluyen sobres cerrados con asignaciones preestablecidas para reducir sesgos introducidos por investigadores.

Consideraciones Finales

Reclutamiento Adecuado

• Es recomendable reclutar más pacientes de los necesarios para compensar posibles pérdidas durante el seguimiento.

Recursos Adicionales

• Existen múltiples recursos web y software disponibles para facilitar procesos estadísticos relacionados con ensayos clínicos.

Understanding Bias in Research Studies

The Impact of Bias on Study Validity

• A biased study is essentially invalid, rendering its results useless. Researchers must analyze their databases for bias to ensure the integrity of their findings.

• If a study is found to be biased, it should be discarded as it wastes time and resources without answering important research questions.

What is Blinding in Research?

• Blinding, or masking, involves keeping participants and researchers unaware of treatment assignments to prevent bias. This includes patients, doctors, and study personnel.

• During discussions about blinding, opinions vary on who should remain blinded; however, most agree that nearly all involved parties should not know treatment allocations except for specific monitoring committees.

Types of Blinding in Clinical Trials

Open Label Studies

• An open label study allows both patients and researchers to know the treatment being administered; this type is prone to biases due to lack of concealment. An example includes comparing surgery with a standard device where the nature of treatments differs significantly.

Simple Blinding

• In simple blinding, only the patient remains unaware of their treatment while the treating physician knows; this can introduce significant information bias from patients based on their knowledge of receiving active versus placebo treatments.

Double-Blind Studies: The Gold Standard

Definition and Importance

• Double-blind studies are designed so that neither patients nor evaluators know which treatment is being given; this minimizes bias effectively and enhances methodological rigor. Consent forms must clearly inform participants about this aspect before they agree to participate in the trial.

Challenges in Maintaining Blinding

• Despite efforts for double blinding, there may be instances where patients can deduce their treatment based on side effects or other indicators (e.g., somnolence). Researchers must navigate these challenges carefully while ensuring ethical standards are upheld regarding patient information disclosure.

Allocation Concealment: Ensuring Fairness

Key Principles

• Allocation concealment ensures that both groups (experimental and control) appear identical concerning appearance and characteristics to avoid unintentional biases during recruitment or participation phases. This includes using neutral packaging without identifiers for medications assigned to participants.

Role of Pharmacy Personnel

• While pharmacy staff need access to treatment allocation lists for dispensing purposes, they should not influence participant care or data management directly related to clinical outcomes during trials. Their role is strictly logistical rather than evaluative or analytical within the context of the trial's methodology.

Who Should Remain Unaware?

Individuals Involved in Trials

• All individuals directly involved in managing or analyzing clinical trials—patients, physicians, evaluators—should remain blinded regarding treatment assignments throughout the study duration to mitigate potential biases effectively.

Ethical Considerations

• It’s crucial that sponsors do not have knowledge about treatment allocations as it could lead to conflicts of interest affecting trial integrity; transparency regarding funding sources is essential but does not justify involvement in data handling processes during trials.

Handling Adverse Events in Clinical Trials

Ethical Considerations and Patient Management

• In the event of a serious adverse event, the decision to allow a patient to continue in the study or withdraw them depends on ethical committee guidelines and safety assessments.

• The researcher and ethics committee play crucial roles in determining whether the patient should remain in the trial, as their benefits from randomization may be compromised.

Role of Data Monitoring Committees

• A Data Safety Monitoring Board (DSMB), composed of statisticians and medical experts, periodically reviews data to ensure therapeutic uncertainty principles are upheld.

• If one treatment shows significantly more adverse events than another, the DSMB has the authority to halt the study prematurely for safety reasons.

Statistical Guidelines for Stopping Studies

• Stopping rules are statistical criteria that dictate when a clinical trial should be terminated based on predefined thresholds of adverse events.

• The statistician responsible for monitoring these rules may have access to unblinded data but must maintain objectivity during analysis.

Importance of Blinding in Clinical Trials

• Ideally, clinical trials should be double-blind; neither patients nor outcome assessors should know treatment assignments to minimize bias.

• All personnel involved in the study—including nurses, monitors, and statisticians—should ideally remain blinded to prevent both intentional and unintentional biases.

Maintaining Blinding Throughout the Study

• Procedures must be implemented to preserve blinding throughout the trial; if any staff must be unmasked due to circumstances, they should not participate further in study activities.

Conclusion and Future Discussions

• The session concludes with an overview of methodological aspects discussed regarding clinical trials. Future sessions will cover practical implications and comparisons between observational studies and experimental studies.